Literature DB >> 16122076

Prevalence and risk factors for vaginal candidiasis among women seeking primary care for genital infections in Dar es Salaam, Tanzania.

L A Namkinga1, M I N Matee, A K Kivaisi, C Moshiro.   

Abstract

OBJECTIVE: To determine the prevalence and risk factors for vaginal candidiasis (VC) among women seeking primary care for genital infections.
DESIGN: Cross-sectional study.
SETTING: Ilala Municipal Hospital in Dar es Salaam, Tanzania.
SUBJECTS: Four hundred and sixty four women presenting with complaints of genital infections.
RESULTS: Of the 464 women examined, 177 (38.1%) had abnormal vaginal discharge, 68(14.7%) had genital ulcers, 272 (58.6%) had genital pruritus, 18 (3.9%) had genital warts and 58 (12.5%) had chancre. The prevalencies of VC, bacterial vaginosis, HIV, T vaginalis, N. gonorrhoeae and syphilis were 45%, 48.4%, 22%, 93%, 1.5% and 4.3%, respectively. The occurrence of VC was positively associated with HIV, (OR = 1.81, 95% CI (1.0-2.67), bacterial vaginosis; (OR = 2.6, 95% CI (1.7-3.9), genital pruritus; (OR = 1.8 1, 95% CI (1.2-2.7) genital discharge; (OR = 1.867, 95% (1.28-2.73) and negatively with T. vaginalis (OR = 0.27, 95% CI (0.12 - 0.6), occupation (OR = 0.65, 95% CI (0.35-0.86)) and with education (OR = 0.43, 95% CI (0.11-0.73). There were increased but non-significant odds for VC in patients with syphilis (OR = 1.6 95% CI (0.6-4.3) and venereal warts (OR = 2.5 95% CI (0.92-6.8) VC was not associated with N. gonorrhoeae, genital ulcers, age at first intercourse, number of sexual partners, marital status or antibiotic usage.
CONCLUSION: The high prevalence of vaginal candidiasis among women with genital infections should be taken into account when updating policies concerning syndromic management of sexually transmitted diseases. More gender specific approach to syndromic management of sexually transmitted infections in females should be considered.

Entities:  

Mesh:

Year:  2005        PMID: 16122076     DOI: 10.4314/eamj.v82i3.9270

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  6 in total

1.  Periodic presumptive treatment for women with prevalent vaginal infections: secondary analysis of data from a randomized controlled trial.

Authors:  Vernon Mochache; Raymond Scott McClelland; Jennifer E Balkus
Journal:  Sex Transm Dis       Date:  2014-07       Impact factor: 2.830

2.  Prevalence, species distribution and antifungal susceptibility of Candida albicans causing vaginal discharge among symptomatic non-pregnant women of reproductive age at a tertiary care hospital, Vietnam.

Authors:  Do Ngoc Anh; Dao Nguyen Hung; Tran Viet Tien; Vu Nhat Dinh; Vu Tung Son; Nguyen Viet Luong; Nguyen Thi Van; Nguyen Thi Nhu Quynh; Nguyen Van Tuan; Le Quoc Tuan; Nguyen Duy Bac; Nguyen Khac Luc; Le Tran Anh; Do Minh Trung
Journal:  BMC Infect Dis       Date:  2021-06-03       Impact factor: 3.090

3.  The relationship between family planning methods, individual hygiene, and fertility with vaginal infections among the women referring to selected health centers in Isfahan city.

Authors:  Mahboubeh Valiani; Maryam Zolfaghari; Maryam Nazemi; Masoumeh Pirhadi; Shokouh Ebrahimian
Journal:  Iran J Nurs Midwifery Res       Date:  2011

4.  Screening of Tanzanian medicinal plants for anti-Candida activity.

Authors:  Deborah K B Runyoro; Mecky I N Matee; Olipa D Ngassapa; Cosam C Joseph; Zakaria H Mbwambo
Journal:  BMC Complement Altern Med       Date:  2006-03-30       Impact factor: 3.659

5.  Phenotypic Detection of Genitourinary Candidiasis among Sexually Transmitted Disease Clinic Attendees in Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria.

Authors:  Oluranti J Obisesan; Olugbenga A Olowe; Samuel S Taiwo
Journal:  J Environ Public Health       Date:  2015-05-07

6.  Prevalence, incidence and risk factors for anogenital warts in Sub Saharan Africa: a systematic review and meta analysis.

Authors:  Cecily Banura; Florence M Mirembe; Jackson Orem; Anthony K Mbonye; Simon Kasasa; Edward K Mbidde
Journal:  Infect Agent Cancer       Date:  2013-07-10       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.